# IL18RAP Gene: Structure, Function, and Clinical Significance


## Key Takeaways

-   IL18RAP is a crucial non-ligand-binding subunit of the IL-18 receptor complex, essential for high-affinity IL-18 binding and subsequent pro-inflammatory signaling via MyD88, IRAK, and TRAF6, leading to NF-κB and AP-1 activation.
-   The *IL18RAP* gene is located at 2q12.1 within a conserved IL-1R family gene cluster, and its expression is tightly regulated by transcription factors like T-bet and NF-κB, with epigenetic modifications (DNA methylation, histone acetylation) playing a significant role.
-   Alternative splicing generates a soluble isoform (sIL-18RAP) that acts as a decoy receptor, modulating the overall IL-18 signaling potency, while the canonical membrane-bound isoform mediates signal transduction through its extracellular Ig-like domains and intracellular TIR domain.
-   Numerous disease-associated SNPs, particularly intronic variants like rs917997, are linked to autoimmune (Celiac, T1D, Crohn's) and inflammatory (Asthma) diseases by altering *IL18RAP* expression, often leading to reduced IFN-γ production.
-   Rare coding variants, such as L402P in the TIR domain, can cause severe loss-of-function, exemplified by aggressive neonatal Type 1 Diabetes, while 3'UTR variants may offer protection against neurodegenerative diseases like ALS by increasing IL18RAP expression.
-   Therapeutic strategies target the IL-18 pathway using monoclonal antibodies against IL-18 or IL-18Rα, recombinant IL-18 binding protein, or potentially small-molecule inhibitors of the TIR domain or downstream kinases, with pharmacogenomic implications for treatment response.

---

## Executive Summary & Key Metadata

The Interleukin-18 Receptor Accessory Protein (IL18RAP) is a critical, non-ligand-binding subunit of the heterodimeric interleukin-18 (IL-18) receptor complex. Encoded by the *IL18RAP* gene, this type I transmembrane protein is indispensable for the high-affinity binding of IL-18 and the subsequent initiation of pro-inflammatory signaling cascades. Beyond its canonical role in T-helper 1 (Th1) and natural killer (NK) cell responses, IL18RAP has emerged as a central node in the pathophysiology of numerous autoimmune, inflammatory, infectious, and neoplastic diseases. Its genomic locus, situated within a cluster of interleukin-1 receptor family genes, is a hotspot for disease-associated single nucleotide polymorphisms (SNPs) that modulate gene expression and signaling potency. This reference manual provides an exhaustive analysis of the *IL18RAP* gene, from its genomic architecture and 3D protein structure to its complex signaling networks, clinical mutation spectrum, and pharmacogenomic relevance.

| **Feature** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | IL18RAP |
| **UniProt Accession** | O95256 |
| **Representative PDB ID** | True (e.g., 3WO4 for the IL-18/IL-18Rα/IL-18RAP complex) |
| **Chromosomal Locus** | 2q12.1 |
| **Primary Molecular Function** | Cytokine receptor accessory protein; signal transduction for IL-18; NF-κB and AP-1 activation |
| **Disease & Pathology Associations** | Celiac disease, Crohn's disease, Type 1 Diabetes, Asthma, Atopy, Leprosy, Myocardial Infarction, Lumbar Disc Degeneration, Cancers, ALS, Dengue Fever |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Cluster Architecture

The *IL18RAP* gene is located on the long (q) arm of chromosome 2, specifically at cytogenetic band **2q12.1**. This region is a highly conserved, gene-dense cluster of the interleukin-1 receptor (IL-1R) family, which includes *IL1R1*, *IL1R2*, *IL1RL1* (ST2), *IL18R1*, and *IL18RAP* [1, 2]. The genomic organization of this cluster is critical for coordinated transcriptional regulation, as shared enhancer elements and topologically associating domains (TADs) can influence the expression of multiple genes simultaneously. The *IL18RAP* gene is oriented in a head-to-tail manner with its partner gene *IL18R1*, which encodes the ligand-binding alpha subunit (IL-18Rα). This tandem arrangement is evolutionarily conserved, underscoring the functional interdependence of the two proteins.

The human *IL18RAP* gene spans approximately 35 kilobases (kb) of genomic DNA. The primary transcript consists of 12 exons, which are alternatively spliced to generate multiple isoforms. The canonical transcript (NM_003853.4) encodes a 599-amino acid precursor protein, which includes a signal peptide, an extracellular domain, a single-pass transmembrane domain, and a cytoplasmic Toll/Interleukin-1 Receptor (TIR) domain.

### 1.2 Promoter Architecture and Transcriptional Regulation

The promoter region of *IL18RAP* lacks a canonical TATA box but contains a high-density CpG island, characteristic of constitutively expressed or rapidly inducible immune genes. This CpG island is a target for DNA methylation, and its methylation status has been linked to gene expression variability and disease susceptibility [3, 4]. Several transcription factor binding sites (TFBS) have been identified within the proximal promoter and distal enhancer regions.

- **T-bet (TBX21):** The Th1-specific transcription factor T-bet is a master regulator of *IL18RAP* expression. Chromatin immunoprecipitation (ChIP) studies have demonstrated that T-bet binds directly to the *IL18RAP* promoter and an upstream enhancer, recruiting histone acetyltransferases (HATs) to open the chromatin structure [5, 6]. Genetic variants that disrupt T-bet binding motifs are associated with altered *IL18RAP* expression in mucosal inflammatory diseases [6].
- **NF-κB:** The promoter contains multiple functional NF-κB response elements. Upon IL-18 receptor activation, the NF-κB pathway is engaged, creating a positive feedback loop that rapidly upregulates *IL18RAP* transcription, thereby increasing cellular sensitivity to IL-18 [7].
- **STAT Transcription Factors:** Signal Transducers and Activators of Transcription (STATs), particularly STAT4 and STAT1, which are activated downstream of IL-12 and interferons, synergize with T-bet to enhance *IL18RAP* expression. This regulatory network is central to the amplification of the Th1 immune response.
- **Epigenetic Regulation:** Histone acetylation patterns at the *IL18RAP* locus are dynamically regulated. Unlike the *IFNG* and *TBET* genes, which show preferential acetylation in Th1 cells, *IL18RAP* exhibits a distinct acetylation profile, suggesting a more complex, multi-step activation process [5]. DNA methylation at CpG sites within the gene body and promoter is inversely correlated with expression, and this epigenetic mark is heritable and modifiable by environmental factors [3, 4].

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of the *IL18RAP* primary transcript generates several isoforms with distinct functional properties.

- **Isoform 1 (Canonical, IL-18RAP-001):** This is the full-length, membrane-bound form (599 aa). It is the primary functional isoform responsible for signal transduction.
- **Isoform 2 (Soluble, IL-18RAP-002):** This isoform results from the inclusion of an alternative exon that introduces a premature stop codon, leading to a truncated protein that lacks the transmembrane and cytoplasmic domains. This soluble IL-18RAP (sIL-18RAP) is secreted into the extracellular space, where it can act as a decoy receptor, sequestering IL-18 and inhibiting the formation of the functional signaling complex. The balance between membrane-bound and soluble isoforms is a critical regulatory checkpoint for IL-18 activity.
- **Isoform 3 (IL-18RAP-003):** This variant lacks a portion of the extracellular domain due to the skipping of exons 3 and 4. The functional significance of this isoform is less well-characterized, but it may modulate receptor assembly or ligand binding.

The regulation of splicing is tissue-specific and can be altered in disease states. For instance, inflammatory stimuli can shift the splicing pattern towards the membrane-bound isoform, increasing cellular responsiveness to IL-18.

## 2. 3D Protein Domain Architecture & Structural Biology

The IL18RAP protein is a type I transmembrane glycoprotein belonging to the interleukin-1 receptor (IL-1R) superfamily. Its three-dimensional structure is critical for its function as a signal-transducing accessory protein. The protein is organized into three major structural and functional domains: an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular Toll/Interleukin-1 Receptor (TIR) domain.

### 2.1 Extracellular Domain (ECD)

The ECD of IL18RAP (approximately amino acids 1-350) is responsible for binding to the IL-18/IL-18Rα complex. It is composed of **three immunoglobulin (Ig)-like domains** (D1, D2, and D3). Each Ig domain adopts a classic β-sandwich fold, consisting of two anti-parallel β-sheets stabilized by a conserved disulfide bond.

- **D1 (Membrane-distal):** This domain makes initial contact with the IL-18 cytokine, contributing to the overall binding affinity.
- **D2 (Middle):** This domain is the primary interface for interaction with the membrane-proximal domain of IL-18Rα. The D2-D3 interface is crucial for the formation of the stable heterodimeric complex.
- **D3 (Membrane-proximal):** This domain is in close proximity to the cell membrane and provides structural rigidity to the receptor complex.

The ECD is heavily **N-glycosylated**, with multiple N-linked glycosylation sites (e.g., Asn-105, Asn-220). These glycan moieties are essential for proper protein folding, cell-surface expression, and stability. The crystal structure of the IL-18/IL-18Rα/IL-18RAP ternary complex (PDB: 3WO4) reveals that IL-18 is sandwiched between the D1 domain of IL-18Rα and the D1 domain of IL-18RAP, with the D2 and D3 domains of IL-18RAP providing additional stabilizing contacts.

### 2.2 Transmembrane Domain (TMD)

The TMD (approximately amino acids 351-373) is a single, highly hydrophobic α-helix that anchors the protein to the plasma membrane. While its primary role is structural, the TMD may also participate in lateral interactions with the IL-18Rα TMD, facilitating the correct orientation of the intracellular domains for signaling.

### 2.3 Intracellular TIR Domain

The cytoplasmic tail of IL18RAP (approximately amino acids 374-599) contains a conserved **Toll/Interleukin-1 Receptor (TIR) domain**. This domain is the signaling hub of the receptor complex. It is composed of a central five-stranded parallel β-sheet surrounded by five α-helices, a fold shared by all members of the TLR/IL-1R superfamily.

The TIR domain of IL18RAP contains three highly conserved sequence motifs, designated **Box 1, Box 2, and Box 3**, which are essential for signal transduction. Upon ligand binding and receptor heterodimerization, the TIR domains of IL-18Rα and IL-18RAP come into close proximity. This dimerization creates a new binding surface that recruits the cytosolic adaptor protein **MyD88 (Myeloid Differentiation Primary Response 88)**. The interaction occurs between the TIR domain of IL18RAP and the TIR domain of MyD88. This event initiates the downstream signaling cascade.

> **[Interactive 3D Protein Visualizer: Load IL18RAP (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95256)**
>
> Use the interactive tool to explore the atomic structure of IL18RAP. The visualizer allows you to rotate the molecule, color-code domains (e.g., Ig-like domains in blue, TIR domain in red), and highlight key residues implicated in disease-associated mutations. This structural context is essential for understanding the functional impact of genetic variants.

## 3. Cellular Signaling Pathways & Molecular Function

IL18RAP is the non-ligand-binding but signal-transducing subunit of the IL-18 receptor. Its primary function is to initiate a potent pro-inflammatory signaling cascade upon IL-18 stimulation.

### 3.1 The IL-18 Signaling Cascade

The signaling pathway is initiated by the formation of a high-affinity ternary complex. IL-18 first binds to the IL-18Rα subunit (encoded by *IL18R1*), which has a low affinity for the cytokine. This binding induces a conformational change in IL-18Rα, creating a binding site for IL18RAP. The recruitment of IL18RAP to the complex forms a high-affinity receptor, and the heterodimerization of the two receptor subunits is the critical step for signal initiation.

```mermaid
sequenceDiagram
    participant IL18 as "IL-18 Cytokine"
    participant Rα as IL-18Rα (IL18R1)
    participant RAP as "IL-18RAP"
    participant MyD88 as "MyD88 Adaptor"
    participant IRAK as "IRAK4/IRAK1"
    participant TRAF6 as "TRAF6"
    participant IKK as "IKK Complex"
    participant NFkB as "NF-κB"
    participant AP1 as "AP-1 (JNK/p38)"
    IL18->>Rα: 1. Low-affinity binding
    Rα->>RAP: 2. Conformational change & recruitment
    RAP->>RAP: 3. TIR domain dimerization
    RAP->>MyD88: 4. TIR-TIR interaction recruits MyD88
    MyD88->>IRAK: 5. Recruits IRAK4 & IRAK1
    IRAK->>TRAF6: 6. Phosphorylation & recruitment of TRAF6
    TRAF6->>IKK: 7. Ubiquitination & activation of IKK
    IKK->>NFkB: 8. Phosphorylation & degradation of IκB
    NFkB->>NFkB: 9. Nuclear translocation
    NFkB->>AP1: 10. Activation of MAPK pathways (JNK/p38)
    NFkB->>Target: 11. Transcription of pro-inflammatory genes (IFNG, TNF, etc.)
    AP1->>Target: 11. Transcription of pro-inflammatory genes
```

1.  **MyD88 Recruitment:** The dimerized TIR domains of IL-18Rα and IL18RAP recruit the cytosolic adaptor protein MyD88. This interaction is mediated by homotypic TIR-TIR domain interactions.
2.  **IRAK Activation:** MyD88 then recruits members of the Interleukin-1 Receptor-Associated Kinase (IRAK) family, primarily IRAK4 and IRAK1. IRAK4 phosphorylates IRAK1, leading to its activation.
3.  **TRAF6 Engagement:** Activated IRAK1 dissociates from the receptor complex and interacts with the E3 ubiquitin ligase TNF Receptor Associated Factor 6 (TRAF6). TRAF6, in conjunction with the Ubc13/Uev1A E2 complex, catalyzes the synthesis of K63-linked polyubiquitin chains on itself and other target proteins.
4.  **Kinase Cascade Activation:** The polyubiquitin chains serve as a scaffold for the recruitment of the TAK1 (TGF-β-Activated Kinase 1) complex and the IKK (IκB Kinase) complex. TAK1 phosphorylates and activates IKKβ.
5.  **NF-κB and AP-1 Activation:** The IKK complex phosphorylates IκBα, targeting it for proteasomal degradation. This releases NF-κB (p50/p65 heterodimer), allowing it to translocate to the nucleus. Simultaneously, TAK1 activates the MAPK pathways (JNK and p38), leading to the activation of the AP-1 transcription factor.
6.  **Transcriptional Response:** NF-κB and AP-1 cooperatively drive the expression of a vast array of pro-inflammatory genes, including *IFNG* (Interferon-gamma), *TNF* (Tumor Necrosis Factor), *IL6*, *IL1B*, and chemokines like *CXCL8* [8, 9].

### 3.2 Functional Role in Immune Cells

IL18RAP is predominantly expressed on cells of the immune system, particularly:

- **T-helper 1 (Th1) Cells:** IL-18, in synergy with IL-12, is a potent inducer of IFN-γ production in Th1 cells. IL18RAP expression is a hallmark of the Th1 lineage, and its upregulation is dependent on T-bet [5, 6].
- **Natural Killer (NK) Cells:** IL-18 is a key activator of NK cell cytotoxicity and cytokine production. IL18RAP is constitutively expressed on NK cells, allowing for rapid responses to IL-18.
- **Macrophages and Monocytes:** These innate immune cells express IL18RAP and respond to IL-18 by producing pro-inflammatory cytokines, contributing to the amplification of the inflammatory response.
- **CD8+ T Cells:** IL-18 enhances the effector functions of cytotoxic T lymphocytes.

### 3.3 Protein-Protein Interaction Networks

Beyond MyD88, IL18RAP interacts with a network of proteins that modulate its function. The primary interaction is with IL-18Rα, forming the functional receptor complex. The TIR domain also interacts with other adaptor proteins, such as **MAL/TIRAP** in certain contexts, although MyD88 is the primary mediator. The expression and function of IL18RAP are also modulated by interactions with negative regulators, such as **SIGIRR (Single Ig IL-1R-Related Molecule)**, which can sequester the receptor complex and inhibit signaling [10]. The protein is also part of a broader interactome involving components of the NF-κB pathway, as identified by high-throughput screens.

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

The *IL18RAP* gene is highly polymorphic, and numerous genetic variants, particularly single nucleotide polymorphisms (SNPs), have been associated with a wide spectrum of human diseases. These variants often exert their effects by altering gene expression levels rather than by changing the amino acid sequence of the protein.

### 4.1 Key Risk SNPs and Their Functional Consequences

- **rs917997 (Intronic):** This is the most extensively studied *IL18RAP* variant. It is located in intron 1 and is strongly associated with **Celiac Disease (CD)** [1, 2, 3], **Type 1 Diabetes (T1D)** [4, 8], **Crohn's Disease (CD)** [5], and **Asthma** [2]. Functional studies have shown that the risk allele (T) is associated with decreased *IL18RAP* expression in peripheral blood mononuclear cells (PBMCs) [8]. This reduced expression leads to diminished IL-18/IL-18R signaling and decreased IFN-γ production, which paradoxically may skew the immune response towards a Th2 or regulatory phenotype, contributing to autoimmunity [6, 8]. The variant is also a cis-eQTL, influencing the expression of not only *IL18RAP* but also neighboring genes like *IL18R1* and *IL1RL1* [7].
- **rs1420100 (Intronic):** This SNP is associated with **Asthma and Atopy** [2], **Lumbar Disc Degeneration (LDD)** [8, 9], and **Cervical Spondylotic Myelopathy (CSM)** [10]. It is also a cis-eQTL for *IL18RAP* expression in neutrophils [1]. The risk allele is linked to altered expression levels, which may influence the intensity of inflammatory responses in affected tissues.
- **rs11465697 (Intronic):** Associated with **Leprosy** [2] and **Inflammatory Bowel Disease (IBD)** [3]. This variant is in linkage disequilibrium with other functional SNPs in the region.
- **rs1420106 (Intronic):** Associated with **Myocardial Infarction (MI)** risk in patients with stable coronary artery disease (CAD) [4, 5]. It is also associated with altered IL-18 plasma levels [4].
- **rs6712512 (Intronic):** Associated with **Lumbar Disc Degeneration** [6, 7] and **Chronic Low Back Pain** [8].

### 4.2 Rare Coding Variants

While most disease-associated variants are non-coding, rare coding mutations can have profound effects.

- **Leu402Pro (L402P):** A missense mutation located in the TIR domain of IL18RAP. This mutation was identified in a patient with **aggressive neonatal Type 1 Diabetes Mellitus** [9]. The substitution of a highly conserved hydrophobic leucine with a rigid proline residue is predicted to disrupt the α-helical structure of the TIR domain, severely impairing the protein's ability to interact with MyD88 and transduce signals. This loss-of-function mutation highlights the critical role of IL18RAP in immune regulation and the development of self-tolerance.

### 4.3 3'UTR Variants and Neurodegeneration

A recent whole-genome sequencing study identified rare variants in the **3' untranslated region (UTR)** of *IL18RAP* that are associated with **protection against Amyotrophic Lateral Sclerosis (ALS)** [10]. These variants are located in a region that is a target for microRNAs (miRNAs). The protective variants are predicted to disrupt miRNA binding, leading to increased IL18RAP expression. This finding suggests that enhanced IL-18 signaling may be neuroprotective in the context of ALS, potentially by modulating microglial function and neuroinflammation.

### 4.4 Clinical Differentials and Disease Associations

The clinical spectrum of *IL18RAP* variants is broad, reflecting its central role in inflammation and immunity.

| **Disease** | **Key Variants** | **Proposed Mechanism** |
| :--- | :--- | :--- |
| **Celiac Disease** | rs917997, rs13015714 | Reduced IL18RAP expression, altered Th1/Th17 balance [1, 2, 3] |
| **Crohn's Disease** | rs917997, rs11465697 | Impaired innate immune signaling, altered mucosal barrier function [3, 5, 6] |
| **Type 1 Diabetes** | rs917997, L402P | Reduced IFN-γ production, impaired immune regulation [4, 8, 9] |
| **Asthma & Atopy** | rs1420100, rs917997 | Altered Th2/Th17 responses, airway inflammation [1, 2] |
| **Lumbar Disc Degeneration** | rs1420100, rs6712512 | Increased inflammatory response in the intervertebral disc [6, 8, 9] |
| **Myocardial Infarction** | rs1420106, rs917997 | Altered IL-18 levels, atherosclerotic plaque instability [2, 4, 5] |
| **Leprosy** | rs11465697 | Shared pathogenesis between inflammation and infectious disease [2] |
| **Cancers (HCC, HNSCC, AML)** | Expression changes | Modulation of tumor microenvironment and immune infiltration [3, 4, 5, 10] |
| **Amyotrophic Lateral Sclerosis** | 3'UTR variants (protective) | Increased IL18RAP expression, potential neuroprotection [10] |
| **Dengue Fever** | Expression changes | Immune and vascular modulation, disease severity [6] |

## 5. Host-Pathogen & Viral Interactions

IL18RAP is a key component of the host innate immune response to pathogens, but it is also exploited or modulated by various pathogens to evade immune surveillance.

### 5.1 Bacterial Infections

- **Leprosy (*Mycobacterium leprae*):** Genetic variants in *IL18RAP* are established risk factors for leprosy [2]. The IL-18/IL18RAP axis is crucial for the cell-mediated immune response required to contain *M. leprae* infection. Variants that reduce IL18RAP expression impair the Th1 response, allowing for bacterial dissemination.
- **Sepsis (*Staphylococcus aureus*, *E. coli*):** IL18RAP expression is significantly upregulated in the blood of patients with sepsis [9]. This upregulation is part of the systemic inflammatory response syndrome (SIRS) to bacterial infection. The IL-18 pathway is a potential therapeutic target in sepsis, and modulating IL18RAP function could dampen the hyper-inflammatory state [7, 8].
- **Tuberculosis (*Mycobacterium tuberculosis*):** IL18RAP is part of a shared hub-gene signature between IPF and TB, suggesting a role in the pulmonary inflammatory response to mycobacterial infection [9].
- **Mastitis (Bovine):** In dairy cattle, *IL18RAP* expression is altered during *E. coli* and *S. aureus* mastitis, indicating its role in the mammary gland's innate immune defense [10].

### 5.2 Viral Infections

- **Dengue Virus (DENV):** IL18RAP expression is modulated during dengue virus infection. Studies have shown that Human Endogenous Retroviruses (HERVs) can influence the expression of IL18RAP and other immune genes, contributing to the severity of dengue disease [6]. The IL-18 pathway is thought to contribute to the "cytokine storm" observed in severe dengue.
- **Epstein-Barr Virus (EBV):** In EBV-associated Natural Killer/T-cell Lymphoma (NKTCL), the tumor microenvironment is characterized by an inflammatory signature. While the direct interaction is not fully defined, the IL-18 pathway, including IL18RAP, is likely involved in the chronic inflammation that promotes tumorigenesis [1].
- **Herpesviruses:** Genetic variation in IL18RAP has been investigated as a candidate gene for schizophrenia, with a hypothesis that interactions between herpesvirus infections and genetic variants in immune genes like IL18RAP may contribute to disease pathogenesis [2].
- **COVID-19 (SARS-CoV-2):** The IL-18 pathway is implicated in the hyper-inflammatory response seen in severe COVID-19. Expression quantitative trait methylation (eQTM) analysis has identified IL18RAP as a gene whose expression is associated with DNA methylation changes in early COVID-19, reflecting disease severity and recovery [3].

### 5.3 Viral Evasion Mechanisms

While no viral protein has been shown to directly bind IL18RAP, several viruses encode homologs of IL-18 binding proteins (IL-18BPs) that neutralize IL-18, thereby preventing the activation of the IL-18Rα/IL18RAP complex. For example, poxviruses and molluscum contagiosum virus secrete soluble IL-18BPs that bind IL-18 with high affinity, acting as decoys to suppress the host's Th1 immune response. This indirectly inhibits IL18RAP-mediated signaling.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

The central role of IL18RAP in inflammatory and autoimmune diseases makes it an attractive therapeutic target. Current strategies focus on modulating the IL-18 signaling pathway at various levels.

### 6.1 Monoclonal Antibodies and Biologics

- **Anti-IL-18 Antibodies (e.g., GSK1070806):** These are humanized monoclonal antibodies that bind to and neutralize IL-18, preventing it from engaging with the IL-18Rα/IL18RAP receptor complex. This approach has been investigated in clinical trials for conditions such as type 2 diabetes, rheumatoid arthritis, and adult-onset Still's disease. By neutralizing the ligand, these antibodies effectively block IL18RAP-mediated signaling.
- **Anti-IL-18Rα Antibodies:** Antibodies targeting the ligand-binding subunit (IL-18Rα) are also in development. These would directly block the initial step of receptor complex formation, preventing the recruitment of IL18RAP.
- **Recombinant IL-18 Binding Protein (rIL-18BP):** Tadekinig alfa is a recombinant form of the human IL-18 binding protein. It acts as a natural decoy, binding to IL-18 and preventing its interaction with the cell surface receptor. This has shown efficacy in treating conditions like NLRC4-mutation-associated autoinflammatory syndromes.

### 6.2 Small-Molecule Inhibitors

- **TIR Domain Inhibitors:** The TIR domain of IL18RAP is a potential target for small-molecule inhibitors. By blocking the TIR-TIR interaction between IL18RAP and MyD88, these molecules could specifically disrupt IL-18 (and IL-1) signaling. However, the high degree of homology between TIR domains across the TLR/IL-1R family makes achieving selectivity a major challenge. This is an active area of drug discovery research.
- **Kinase Inhibitors:** Downstream kinases, such as IRAK4, are also druggable targets. IRAK4 inhibitors are being developed for various inflammatory diseases and could indirectly block the effects of IL18RAP activation.

### 6.3 Pharmacogenomic Implications

The pharmacogenomics of *IL18RAP* is an emerging field. Genetic variants that alter IL18RAP expression or function can influence an individual's response to therapy.

- **Anti-TNF Therapy in Rheumatoid Arthritis (RA):** A study investigating genetically regulated gene expression found a significant association between *IL18RAP* expression and response to anti-TNF treatment in RA patients [3]. Patients with genetically predicted higher *IL18RAP* expression showed a better response to treatment, suggesting that IL18RAP expression levels could serve as a predictive biomarker for therapy selection.
- **Targeted Therapy in Melanoma:** Gene expression signatures, including those involving immune reinduction pathways, have been identified as potential biomarkers of response to targeted therapy in metastatic melanoma [4]. IL18RAP, as part of the broader immune response, may contribute to these signatures.
- **Statins:** In vitro studies have shown that statins (simvastatin and rosuvastatin) can modulate global gene expression in peripheral blood leukocytes, potentially affecting inflammatory pathways involving IL18RAP [5]. This suggests a potential pharmacodynamic interaction.

### 6.4 Gene Therapy and RNA-Based Therapeutics

- **Antisense Oligonucleotides (ASOs) and siRNA:** These approaches could be used to downregulate *IL18RAP* expression in conditions where its activity is pathogenic. Conversely, for diseases where increased expression is protective (e.g., ALS), upregulation strategies using CRISPR activation (CRISPRa) could be explored.
- **CRISPR-Cas9 Gene Editing:** In principle, CRISPR-Cas9 could be used to correct pathogenic mutations in *IL18RAP* or to introduce protective variants. However, this approach is still in its infancy for complex inflammatory diseases.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the *IL18RAP* gene and protein.

| **Database** | **Identifier / Accession** | **Description** |
| :--- | :--- | :--- |
| **HGNC** | HGNC:5985 | Official gene symbol and name |
| **NCBI Gene** | Gene ID: 8807 | Gene-centric information, genomic context, and links |
| **Ensembl** | ENSG00000115607 | Genome assembly, transcripts, and variation data |
| **UniProtKB** | O95256 | Protein sequence, function, and post-translational modifications |
| **RCSB PDB** | 3WO4 (and others) | Experimentally determined 3D structures of the protein complex |
| **OMIM** | 607337 | Mendelian inheritance and disease associations |
| **ClinVar** | Gene: IL18RAP | Human variations and their relationship to disease |
| **STRING** | 9606.ENSP00000264031 | Protein-protein interaction networks |
| **BioGRID** | 112431 | Physical and genetic interactions |
| **Gene Ontology (GO)** | GO:0004872 (receptor activity), GO:0007165 (signal transduction), GO:0006954 (inflammatory response) | Functional annotations (Molecular Function, Biological Process, Cellular Component) |
| **GTEx Portal** | IL18RAP | Expression quantitative trait loci (eQTLs) and tissue-specific expression |
| **GWAS Catalog** | EFO_0003767 (IL18RAP) | All published GWAS associations for the gene |

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Wang, X., Zhu, Y., Li, D. M., Qin, Q., Wang, Q., Muhali, F., Jiang, W. J., & Zhang, J. A. (2016). Polymorphisms of ST2‐IL18R1‐IL18RAP gene cluster: a new risk for autoimmune thyroid diseases. *International Journal of Immunogenetics*. https://www.semanticscholar.org/paper/32dbf0c7ee6211f51e403ac944734cadaaec1c0e

[2] Diptiranjan, S., Harshitha, S., Sibin, M., Arati, S., Chetan, G., & Bhat, D. (2019). Role of APOE and IL18RAP gene polymorphisms in cervical spondylotic myelopathy in Indian population. *Journal of Clinical Neuroscience*. https://www.semanticscholar.org/paper/3ef601f3aabc8404e4883c8feb9814aa06a991c2

[3] Martínez-Barquero, V., de Marco, G., Martínez-Hervás, S., Adam-Felici, V., Pérez-Soriano, C., González-Albert, V., Rojo, G., Ascaso, J., Real, J., García-García, A., Martín-Escudero, J., Cortes, R., & Chaves, F. (2017). Are IL18RAP gene polymorphisms associated with body mass regulation? A cross-sectional study. *BMJ Open*. https://www.semanticscholar.org/paper/6e4f1278fb0d1c9e78c7e0b96030f2e98f98d59e

[4] Dirlewanger, M., Blouin, J., Bevillard, J., Santoni, F., & Schwitzgebel, V. (2014). A leu402pro Mutation of the Non-hla Gene il18rap in Aggressive Neonatal Type 1 Diabetes Mellitus. *Scientific Publication*. https://www.semanticscholar.org/paper/0a8bbebf436d700f6b8f543e0d47bbe0e89b64f9

[5] Surovtseva, M. N., Vainer, A. S., Vainer, A. S., Berezina, O., Ovchinnikov, V., Voropaeva, E., Pospelova, T., & Filipenko, M. L. (2014). Analysis of the Association of Polymorphic Loci rs917997 in IL18RAP Gene and rs187238 in IL18 Gene with the Risk for Non-Hodgkin’s Malignant Lymphomas in Novosibirsk Population. *Bulletin of Experimental Biology and Medicine*. https://www.semanticscholar.org/paper/7e00f9c84a2fd601b0af96d29054b8b350bf9a33

[6] Reijmerink, N., Postma, D., Bruinenberg, M., Nolte, I., Meyers, D., Bleecker, E., & Koppelman, G. (2008). Association of IL1RL1, IL18R1, and IL18RAP gene cluster polymorphisms with asthma and atopy. *Journal of Allergy and Clinical Immunology*. https://www.semanticscholar.org/paper/5b9b241a6daf6b62839e3d7a0881ede46dd18d11

[7] Cherlin, S., Lewis, M. J., Plant, D., Nair, N., Goldmann, K., Tzanis, E., Barnes, M. R., McKeigue, P., Barrett, J., Pitzalis, C., Barton, A., & Cordell, H. (2020). Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response. *Annals of the Rheumatic Diseases*. https://www.semanticscholar.org/paper/756cf9a8ca2aef983bcf0095fa4a11c37edd624b

[8] Ferreira, C., da Silva, A. T., Brustolini, O., Soares, B. R. P., Manuli, E. R., Ramundo, M., Paranhos-Baccalà, G., Sabino, E., & Vasconcelos, A. T. R. (2025). Immune and vascular modulation by HERVs: the role of CXCR1 and IL18RAP in dengue severity progression. *Frontiers in Immunology*. https://www.semanticscholar.org/paper/ff9fd8bc6c8ac53e32094c51749acbcc3f820d3e

[9] Ponasenko, A., Khutornaya, M., Malyshev, I., & Barbarash, O. (2020). Interleukin 18 levels in patients with stable coronary artery disease is associated with IL18RAP and IL18R1 gene polymorphism and the risk of myocardial infarction. *Russian Journal of Cardiology*. https://www.semanticscholar.org/paper/6e2ee5f51396639f14b24a593ca17dd5f6eac33f

[10] Chen, W., Song, T., Zou, F., Xia, Y., Xing, J., Yu, W., Rao, T., Zhou, X., Li, C., Ning, J., Zhao, S., Ruan, Y., & Cheng, F. (2023). Prognostic and